Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Objectives Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …

There is growing evidence that mesenchymal stem cell (MSC)-based immunosuppression
was mainly attributed to the effects of MSC-derived extracellular vesicles (MSC-EVs). MSC …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …

Idiopathic pulmonary fibrosis (IPF) is a fatal and incurable form of interstitial lung disease in
which persistent injury results in scar tissue formation. As fibrosis thickens, the lung tissue …

Mesenchymal stem cell (MSC)-sourced secretome, defined as the set of MSC-derived
bioactive factors (soluble proteins, nucleic acids, lipids and extracellular vesicles), showed …

Mesenchymal stem/stromal cell (MSC)-based therapeutics is already available for treatment
of a range of diseases or medical conditions. Autologous or allogeneic MSCs obtained from …

Idiopathic pulmonary fibrosis (IPF) is a fatal age-associated disease that is characterized by
progressive and irreversible scarring of the lung. The pathogenesis of IPF is not completely …

Chronic lung diseases pose a tremendous global burden. At least one in four people suffer
from severe pulmonary sequelae over the course of a lifetime. Despite substantial …

During acute or chronic lung injury, inappropriate immune response and/or aberrant repair
process causes irreversible damage in lung tissue and most usually results in the …